Protein Tyrosine Phosphatase 1B inhibitors: A molecular level legitimate approach for the management of diabetes mellitus

Medicinal Research Reviews

Volumn 32, Issue 3, 2012, Pages 459-517

  Thareja, Suresh ^a   Aggarwal, Saurabh ^a   Bhardwaj, T R ^a,b   Kumar, Manoj ^a  

^a PANJAB UNIVERSITY   (India)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

Diabetes; Insulin; Metabolism; Obesity; Protein Tyrosine Phosphatase 1B (PTP 1B)

Indexed keywords

2 (OXALYLAMINO)BENZOIC ACID; ACCETOPHENONE DERIVATIVE; BENZIMIDAZOLE; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE BIPHENYL OXOACETIC ACID; BERBERINE; ERTIPROTAFIB; FORMYLCHROMONE DERIVATIVE; IMIDAZOLE DERIVATIVE; IMIDAZOLINE DERIVATIVE; INSULIN; INSULIN RECEPTOR; ISOTHIAZOLIDINONE DERIVATIVE; ISOXAZOLE DERIVATIVE; KR 61639; MULBERROFURAN C; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PYRIDAZINE DERIVATIVE; SANGGENON C; SANGGENON G; THIADIAZOLIDINONE DERIVATIVE; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BINDING; DRUG METABOLISM; DRUG SCREENING; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; GLUCONEOGENESIS; GLUCOSE TRANSPORT; HUMAN; HYDROPHOBICITY; IC 50; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOLECULARLY TARGETED THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; X RAY CRYSTALLOGRAPHY;

ACETOPHENONES; AMINO ACID SEQUENCE; ANIMALS; BENZOFURANS; BENZOIC ACIDS; BIPHENYL COMPOUNDS; BLOOD GLUCOSE; CATALYTIC DOMAIN; CATECHOLS; CHROMONES; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FLUORIDES; HUMANS; INSULIN; INSULIN RESISTANCE; JANUS KINASE 2; MODELS, MOLECULAR; NAPHTHOQUINONES; PEPTIDOMIMETICS; PHOSPHATES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PYRIDAZINES; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; THIAZOLES; THIAZOLIDINEDIONES; THIOPHENES; VANADIUM COMPOUNDS;

EID: 84860342332     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20219     Document Type: Article

References (188)

1. Vats RK, Kumar V, Kothari A. Emerging targets for diabetes mellitus. Curr Sci 2005;88:241-249.
2. Xie M, Gao L, Li L, Liu W, Yan S. A new orally active antidiabetic vanadyl complex-bis(α-furancarboxylato)oxovanadium (IV). J Inorg Biochem 2005;99:546-551.
3. Chaudhry J, Ghosh NN, Roy K, Chandra R. Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats. Life Sci 2007;80:1135-1142.
4. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-787.
5. Schwarz J, Bornstein SR, Schulze J. Prevention of type 2 diabetes: What challenges do we have to address? J Public Health 2005;13:303-308.
6. Sakurai H. A new concept: The use of vanadium complexes in the treatment of diabetes mellitus. Chem Rec 2002;2:237-248.
7. Tomlinson DR. The pharmacology of diabetic neuropathy. Pharmacol Ther 1992;54:151-194.
8. Astrup A, Finer N. Redefining type 2 diabetes: "diabesity" or "obesity dependent diabetes mellitus"? Obesity Rev 2000;1:57-59.
9. Shafrir E. Development and consequences of insulin resistance: Lessons from animals with hyperinsulinaemia. Diabetes Metab 1997;22:131-148.
10. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: Can the doomsday scenario be averted? J Intern Med 2000;247:301-310.
11. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 1998;21:1414-1431.
12. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, Department of Noncommunicable Disease Surveillance, Geneva, 1999.
13. Minoura H, Takeshita S, Yamamoto T, Mabuchi M, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Ita M, Mutoh S. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor-γ agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol 2005;519:182-190.
14. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, Neschen S, Kahn BB, Kahn CR, Shulman GI. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 2000;105:1791-1797.
15. Chakrabarti R, Misra P, Vikramadithyan RK, Premkumar M, Hiriyan J, Datla SR, Damarla RK, Suresh J, Rajagopalan R. Antidiabetic and hypolipidemic potential of DRF (2519-a) dual activator of PPAR-α and PPAR-γ. Eur J Pharmacol 2004;491:195-206.
16. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1495-1507.
17. Mercado M, McLenithan J, Silver K, Shuldiner A. Genetics of insulin resistance. Curr Diab Rep 2002;2:83-95.
18. Bloomgarden ZT. Insulin resistance: Current concepts. Clin Ther 1998;20:216-231.
19. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001;17:107-124.
20. Sachan N, Thareja S, Aggarwal R, Kadam SS, Kulkarni VM. Substituted biphenyl ethanones as antidiabetic agents: Synthesis and in-vivo screening. Int J PharmTech Res 2009;1:1625-1631.
21. Goel A, Agarwal N, Singh FV, Sharon A, Tiwari P, Dixit M, Pratap R, Srivastava AK, Maulik PR, Ram VJ. Antihyperglycemic activity of 2-methyl-3, 4, 5-triaryl-1H-pyrroles in SLM and STZ models. Bioorg Med Chem Lett 2004;14:1089-1092.
22. Singh FV, Parihar A, Chaurasia S, Singh AB, Singh SP, Tamrakar AK, Srivastava AK, Goel A. 5, 6-Diarylanthranilo-1, 3-dinitriles as a new class of antihyperglycemic agents. Bioorg Med Chem Lett 2009;19:2158-2161.
23. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review. Clin Ther 2000;22:1151-1168.
24. Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold CK. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database. Clin Ther 2009;31:2665-2677.
25. Garcia-Barrado M-J, Jonas J-C, Gilon P, Henquin J-C. Sulphonylureas do not increase insulin secretion by a mechanism other than a rise in cytoplasmic Ca2+ in pancreatic B-cells. Eur J Pharmacol 1996;298:279-286.
26. Norman P, Rabasseda X. Nateglinide: A structurally novel, short-acting, hypoglycemic agent. Drugs Today 2001;37:411-426.
27. Purrello F, Gullo D, Brunetti A, Buscema M, Italia S, Goldfine ID, Vigneri R. Direct effects of biguanides on glucose utilization in vitro. Metabolism 1987;36:774-776.
28. Deacon CF, Holst JJ. Saxagliptin: A new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Adv Ther 2009;26:488-499.
29. Deacon CF, Carr RD, Holst JJ. DPP-4 inhibitor therapy: New directions in the treatment of type 2 diabetes. Front Biosci 2008;13:1780-1794.
30. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-2157.
31. Knudsen L. Glucagon-like peptide-1: The basis of a new class of treatment for type II diabetes. J Med Chem 2004;47:4128-4134.
32. Fukaya N, Mochizuki K, Tanaka Y, Kumazawa T, Jiuxin Z, Fuchigami M, Goda T. The α-glucosidase inhibitor miglitol delays the development of diabetes and dysfunctional insulin secretion in pancreatic β-cells in OLETF rats. Eur J Pharmacol 2009;624:51-57.
33. Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Ther 1997;19:720-729.
34. Mouser JF. New drugs for management of diabetes: Insulin analogues, inhaled insulin, pramlintide, and novel peptides. Nutr Clin Pract 2004;19:172-180.
35. Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, Harrison SD. Selective glycogen synthase kinase-3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003;52:588-595.
36. Henke BR. Peroxisome proliferator activated receptor α/γ dual agonist for the treatment of type II diabetes. J Med Chem 2004;47:4118-4127.
37. Asano T, Ogihara T, Katagiri H, Sakoda H, Ono H, Fujishiro M, Anai M, Kurihara H, Uchijima Y. Glucose transporter and Na+/glucose co transporter as molecular targets of anti-diabetic drugs. Curr Med Chem 2004;11:2717-2724.
38. Home PD, Pacini G. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: A critical target for insulin-sensitizing agents. Diabetes Obes Metab 2008;10:699-718.
39. Arch JRS, Wilson S. Prospects for β3-adrenoceptor agonists in the treatment of obesity and diabetes. Int J Obes 1996;20:191-199.
40. Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes. Receptor Channels 2001;7:249-258.
41. Pei Z, Liu G, Lubben TH. Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity. Curr Pharm Des 2004;10:3481-3504.
42. Lammers R, Møller PH, Ullrich A. The transmembrane protein tyrosine phosphatase α dephosphorylates the insulin receptor in intact cells. FEBS Lett 1997;404:37-40.
43. Huynh H, Bottini N, Williams S, Cherepanov V, Musumeci L, Saito K, Bruckner S, Vachon E, Wang X, Kruger J, Chow C-W, Pellecchia M, Monosov E, Greer PA, Trimble W, Downey GP, Mustelin T. Control of vesicle fusion by a tyrosine phosphatase. Nat Cell Biol 2004;6:831-839.
44. Halazy S. Signal transduction: An exciting field of investigation for small drug molecules. Molecules 2003;8:349-358.
45. Monteiro HP, Stern A. Redox modulation of tyrosine phosphorylation-dependent signal transduction pathways. Free Radic Biol Med 1996;21:323-333.
46. Dewang PM, Hsu N-M, Peng S-Z, Li W-R. Protein tyrosine phosphatases and their inhibitors. Curr Med Chem 2005;12:1-22.
47. He Y, Yan H, Dong H, Zhang P, Tang L, Qiu X, Wu M, Wang H. Structural basis of interaction between protein tyrosine phosphatase PCP-2 and β-catenin. Sci China C Life Sci 2005;48:163-167.
48. Zhang Z-Y. Emerging new techniques for studying protein phosphatases. Methods 2007;42:205-206.
49. Bhattacharya S, LaButti JN, Seiner DR, Gates KS. Oxidative inactivation of protein tyrosine phosphatase 1B by organic hydroperoxides. Bioorg Med Chem Lett 2008;18:5856-5859.
50. Hunter T. Signaling-2000 and beyond. Cell 2000;100:113-127.
51. Tautz L, Pellecchia M, Mustelin T. Targeting the PTPome in human disease. Expert Opin Ther Targets 2006;10:157-177.
52. Jung KJ, Lee EK, Yu BP, Chung HY. Significance of protein tyrosine kinase/protein tyrosine phosphatase balance in the regulation of NF-[kappa]B signaling in the inflammatory process and aging. Free Radic Biol Med 2009;47:983-991.
53. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
54. Zhang Z-Y. Protein-tyrosine phosphatases: Biological function, structural characteristics, and mechanism of catalysis. Crit Rev Biochem Mol Biol 1998;33:1-52.
55. Zhang Z-Y. Protein tyrosine phosphatases: Prospects for therapeutics. Curr Opin Chem Biol 2001;5:416-423.
56. Protein Phosphatases and Drug Discovery () (2004).
57. Zhang Z-Y, Lee S-Y. PTP 1B inhibitors as potential therapeutics in the treatment of Type 2 diabetes and obesity. Expert Opin Invest Drugs 2003;12:223-233.
58. Kennedy BP. Role of protein tyrosine phosphatase 1B in diabetes and obesity. Biomed Pharmacotherap 1999;53:466-470.
59. Montalibet J, Kennedy BP. Therapeutic strategies for targeting PTP 1B in diabetes. Drug Disc Today 2005;2:129-135.
60. Shifrin VI, Neel BG. Growth factor-inducible alternative splicing of nontransmembrane phosphotyrosine phosphatase PTP 1B pre-mRNA. J Biol Chem 1993;268;25376-25384.
61. Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell 2000;6:1401-1412.
62. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J. The ins and outs of leptin receptor activation. FEBS Lett 2003;546:45-50.
63. Lund IK, Bilestup N. Mechanism of PTP 1B mediated inhibition of leptin signaling. J Mol End 2005;15:339-351.
64. Zhang S, Zhang Z-Y. PTP 1B as a drug target: Recent developments in PTP 1B inhibitor. Drug Discov Today 2005;2:129-135.
65. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Hagen JH, Chan C-C, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999;283:1544-1548.
66. Klaman LD, Boss O, Peroni OD, Kim JK, Martino JL, Zabolotny JM, Moghal N, Lubkin M, Kim Y-B, Sharpe AH, Stricker-Krongrad A, Shulman GI, Neel BG, Kahn BB. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000;20:5479-5489.
67. Rondinone CM, Trevillyan JM, Clampit J, Gum RJ, Berg C, Kroeger P, Frost L, Zinker BA, Reilly R, Ulrich R, Butler M, Monia BP, Jirousek MR, Waring JF. Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis. Diabetes 2002; 51:2405-2411.
68. Bence KK, Delibegovic M, Xue B, Gorgun CZ, Hotamisligil GS, Neel BG, Kahn BB. Neuronal PTP1B regulates body weight, adiposity and leptin action. Nat Med 2006;12:917-924.
69. Martin TL, Alquier T, Asakura K, Furukawa N, Preitner F, Kahn BB. Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J Biol Chem 2006;281:18933-18941.
70. Xue B, Pulinilkunnil T, Murano I, Bence KK, He H, Minokoshi Y, Asakura K, Lee A, Haj F, Furukawa N, Catalano KJ, Delibegovic M, Balschi JA, Cinti S, Neel BG, Kahn BB. Neuronal protein tyrosine phosphatase 1B deficiency results in inhibition of hypothalamic AMPK and isoform-specific activation of AMPK in peripheral tissues. Mol Cell Biol 2009;29:4563-4573.
71. Liu G. Protein tyrosine phosphatases 1B (PTP 1B) inhibition: Opportunities and challenges. Curr Med Chem 2003;10:1407-1421.
72. Kennedy BP, Ramachandran C. Protein tyrosine phosphatase 1B in diabetes. Biochem Pharmacol 2000;60:877-883.
73. Gu F, Nguyen DT, Stuible M, Dube N, Tremblay ML, Chevet E. Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J Biol Chem 2004;279:49689-49693.
74. Delibegovic M, Zimmer D, Kauffman C, Rak K, Hong EG, Cho YR, Kim JK, Kahn BB, Neel BG, Bence KK. Liver-specific deletion of protein tyrosine phosphatase 1B (PTP1B) leads to improved glucose and lipid metabolism and decreased high-fat diet induced ER stress response. Diabetes 2009;58:590-599.
75. Zabolotny JM, Kim Y-B, Welsh LA, Kershaw EE, Neel BG, Kahn BB. Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo. J Biol Chem 2008;283:14230-14241.
76. Nieto-Vazquez I, Fernández-Veledo S, Alvaro C, Rondinone CM, Valverde AM, Lorenzo M. Protein-tyrosine phosphatase 1B-deficient myocytes show increased insulin sensitivity and protection against tumor necrosis factor-α-induced insulin resistance. Diabetes 2007;56:404-413.
77. Delibegovic M, Mody N. Protein tyrosine phosphates 1B (PTP1B) in obesity and type 2 diabetes. Acta Medica Saliniana 2009;38:2-7.
78. Bentires-Alj M, Neel BG. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res 2007;67:2420-2424.
79. Julien SG, Dube N, Read M, Penney J, Paquet M, Han Y, Kennedy BP, Muller WJ, Tremblay ML. Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis. Nat Genet 2007;39:338-346.
80. Arias-Romero LE, Saha S, Villamar-Cruz O, Yip S-C, Ethier SP, Zhang Z-Y, Chernoff J. Activation of Src by protein tyrosine phosphatase 1B is required for ErbB2 transformation of human breast epithelial cells. Cancer Res 2009;69:4582-4588.
81. Koren S, Fantus IG. Inhibition of the protein tyrosine phosphatase PTP1B: potential therapy for obesity, insulin resistance and type-2 diabetes mellitus. Best Pract Res Cl En 2007;21:621-640.
82. Evans JL, Jallal B. Protein tyrosine phosphatases: Their role in insulin action and potential as drug targets. Expert Opin Invest Drugs 1999;8:139-160.
83. Balasubramanyam M, Mohan V. Orally active insulin mimics: Where do we stand now? J Biosci 2001;26:383-390.
84. Evans JL, Jallal B. Protein tyrosine phosphatases: Their role in insulin action and potential as drug targets. Expert Opin Invest Drugs 1999;8:139-160.
85. Seely BL, Staubs PA, Reichart DR, Berhanu P, Milarski KL, Saltiel AR, Kusari J, Olefsky JM. Protein tyrosine phosphatase 1B interacts with the activated insulin receptor. Diabetes 1996;45:1379-1385.
86. Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov 2002;1:696-709.
87. Tonks NK. PTP 1B: From the sidelines to the front lines! FEBS Lett 2003;546:140-148.
88. Pannifer ADB, Flint AJ, Tonks NK, Barford D. Visualization of the cysteinyl-phosphate intermediate of a protein-tyrosine phosphatase by X-ray crystallography. J Biol Chem 1998;273:10454-10462.
89. Kamerlin SCL, Rucker R, Boresch S. A molecular dynamics study of WPD-loop flexibility in PTP 1B. Biochem Biophys Res Commun 2007;356:1011-1016.
90. Groves MR, Yao Z-J, Roller PP, Burke TR, Barford D. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry 1998;37:17773-17783.
91. Hu X, Vujanac M, Erec SC. Computational analysis of tyrosine phosphatase inhibitor selectivity for the virulence factors YopH and SptP. J Mol Graph Model 2004;23:175-187.
92. Goldstein BJ. Protein-tyrosine phosphatases: Emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocrinol Metab 2002;87:2474-2480.
93. Kim H-O, Blaskovich MA. Recent discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin Ther Patents 2002;12:871-905.
94. Swarbrick MM, Havel PJ, Levin AA, Bremer AA, Stanhope KL, Butler M, Booten SL, Graham JL, McKay RA, Murray SF, Watts LM, Monia BP, Bhanot S. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys. Endocrinology 2009;150:1670-1679.
95. Tam S, Saiah E. Recent advances in the discovery and development of PTP-1B inhibitors. Drugs Future 2008;133:175-185.
96. Koyama H, Boueres JK, Han W, Metzger EJ, Bergman JP, Gratale DF, Miller DJ, Tolman RL, MacNaul KL, Berger JP, Doebber TW, Leung K, Moller DE, Heck JV, Sahoo SP. 5-Aryl thiazolidine-2, 4-diones as selective PPAR-γ agonists. Bioorg Med Chem Lett 2003;13:1801-1804.
97. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999;20:649-688.
98. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor (PPAR). J Biol Chem 1995;270:12953-12956.
99. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 2001;52:239-257.
100. Wu Y, Ouyang JP, Wu K, Wang SS, Wen CY, Xia ZY. Rosiglitazone ameliorates abnormal expression and activity of protein tyrosine phosphatase 1B in the skeletal muscle of fat-fed, streptozotocin-treated diabetic rats. Bri J Pharmacol 2005;146:234-243.
101. Delibegovic M, Bence KK, Mody N, Hong E-G, Ko HJ, Kim JK, Kahn BB, Neel BG. Improved glucose homeostasis in mice with muscle-specific deletion of protein-tyrosine phosphatase-1B. Mol Cell Bio 2007;27:7727-7734.
102. Maccari R, Paoli P, Ottanà R, Jacomelli M, Ciurleo R, Manao G, Steindl T, Langer T, Vigorita MG, Camici G. 5-Arylidene-2, 4-thiazolidinediones as inhibitors of protein tyrosine phosphatases. Bioorg Med Chem 2007;15:5137-5149.
103. Maccari R, Ottanà R, Ciurleo R, Paoli P, Manao G, Camici G, Laggner C, Langer T. Structure-based optimization of benzoic acids as inhibitors of protein tyrosine phosphatase 1B and low molecular weight protein tyrosine phosphatase. Chem Med Chem 2009;4:957-962.
104. Bhattarai BR, Kafle B, Hwang JS, Khadka D, Lee SM, Kang JS, Ham SW, Han IO, Park H, Cho H. Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects. Bioorg Med Chem Lett 2009;19:6161-6165.
105. Thareja S, Aggarwal S, Bhardwaj TR, Kumar M. Self organizing molecular field analysis of 2, 4-Thiazolidinediones: A 3D-QSAR model for the development of human PTP 1B inhibitors. Eur J Med Chem 2010;45:2537-2546.
106. Ottanà R, Maccari R, Ciurleo R, Paoli P, Jacomelli M, Manao G, Camici G, Laggner C, Langer T. 5-Arylidene-2-phenylimino-4-thiazolidinones as PTP1B and LMW-PTP inhibitors. Bioorg Med Chem 2009;17:1928-1937.
107. Burke TR. Protein-tyrosine kinase inhibitors. Drugs Future 1992;17:119-131.
108. Yao ZJ, Ye B, Wu XW, Wang S, Wu L, Zhang ZY, Burke JTR. Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors. Bioorg Med Chem 1998;6:1799-1810.
109. Montalibet J, Skorey K, McKay D, Scapin G, Asante-Appiah E, Kennedy BP. Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding. J Biol Chem 2006;281:5258-5266.
110. Hecker SJ, Erion MD. Prodrugs of phosphates and phosphonates. J Med Chem 2008;51:2328-2345.
111. Gao Y, Voigt J, Zhao H, Pais GCG, Zhang X, Wu L, Zhang ZY, Burke TR. Utilization of a peptide lead for the discovery of a novel PTP1B-binding motif. J Med Chem 2001;44:2869-2878.
112. Burke TR, Kole HK, Roller PP. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. Biochem Biophys Res Commun 1994;204:129-134.
113. Leung C, Grzyb J, Lee J, Meyer N, Hum G, Jia C, Liu S, Taylor SD. The difluoromethylenesulfonic acid group as a monoanionic phosphate surrogate for obtaining PTP1B inhibitors. Bioorg Med Chem 2002;10:2309-2323.
114. Li X, Bhandari A, Holmes CP, Szardenings AK. α, α-Difluoro-β-ketophosphonates as potent inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2004;14:4301-4306.
115. Holmes CP, Li X, Pan Y, Xu C, Bhandari A, Moody CM, Miguel JA, Ferla SW, De Francisco MN, Frederick BT, Zhou S, Macher N, Jang L, Irvine JD, Grove JR. Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors. Bioorg Med Chem Lett 2005;15:4336-4341.
116. Holmes CP, Li X, Pan Y, Xu C, Bhandari A, Moody CM, Miguel JA, Ferla SW, De Francisco MN, Frederick BT, Zhou S, Macher N, Jang L, Irvine JD, Grove JR. PTP1B inhibitors: Synthesis and evaluation of difluoro-methylenephosphonate bioisosteres on a sulfonamide scaffold. Bioorg Med Chem Lett 2008;18:2719-2724.
117. Combs AP, Yue EW, Bower M, Ala PJ, Wayland B, Douty B, Takvorian A, Polam P, Wasserman Z, Zhu W, Crawley ML, Pruitt J, Sparks R, Glass B, Modi D, McLaughlin E, Bostrom L, Li M, Galya L, Blom K, Hillman M, Gonneville L, Reid BG, Wei M, Becker-Pasha M, Klabe R, Huber R, Li Y, Hollis G, Burn TC, Wynn R, Liu P, Metcalf B. Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. J Med Chem 2005;48:6544-6548.
118. Yue EW, Wayland B, Douty B, Crawley ML, McLaughlin E, Takvorian A, Wasserman Z, Bower MJ, Wei M, Li Y, Ala PJ, Gonneville L, Wynn R, Burn TC, Liu PCC, Combs AP. Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: Synthesis and structure-activity relationships of a peptide scaffold. Bioorg Med Chem 2006;14:5833-5849.
119. Sparks RB, Polam P, Zhu W, Crawley ML, Takvorian A, McLaughlin E, Wei M, Ala PJ, Gonneville L, Taylor N, Li Y, Wynn R, Burn TC, Liu PCC, Combs AP. Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett 2007;17:736-740.
120. Douty B, Wayland B, Ala PJ, Bower MJ, Pruitt J, Bostrom L, Wei M, Klabe R, Gonneville L, Wynn R, Burn TC, Liu PCC, Combs AP, Yue EW. Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines. Bioorg Med Chem Lett 2008;18:66-71.
121. Ye B, Akamatsu M, Shoelson SE, Wolf G, Giorgetti-Peraldi S, Yan X, Roller PP, Burke TR. L-O-(2-Malonyl)tyrosine: A new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. J Med Chem 1995;38:4270-4275.
122. Burke TR, Ye B, Akamatsu M, Ford H, Yan X, Kole HK, Wolf G, Shoelson SE, Roller PP. 4′-O-[2-(2-Fluoromalonyl)]-l-tyrosine: A phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides1. J Med Chem 1996;39:1021-1027.
123. Pei Z, Liu G, Lubben TH, Szczepankiewicz BZ. Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity. Curr Pharm Des 2004;10:3481-3504.
124. Gao Y, Wu L, Luo JH, Guo R, Yang D, Zhang ZY, Burke TR. Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. Bioorg Med Chem Lett 2000;10:923-927.
125. Xin Z, Liu G, Abad-Zapatero C, Pei Z, Szczepankiewicz BG, Li X, Zhang T, Hutchins CW, Hajduk PJ, Ballaron SJ, Stashko MA, Lubben TH, Trevillyan JM, Jirousek MR. Identification of a monoacid-Based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2003;13:3947-3950.
126. Shrestha S, Bhattarai BR, Chang KJ, Lee KH, Cho H. Methylenedisalicylic acid derivatives: New PTP1B inhibitors that confer resistance to diet-induced obesity. Bioorg Med Chem Lett 2007;17:2760-2764.
127. Shrestha S, Bhattarai BR, Lee KH, Cho H. Mono- and disalicylic acid derivatives: PTP1B inhibitors as potential anti-obesity drugs. Bioorg Med Chem 2007;15:6535-6548.
128. Bhattarai BR, Shrestha S, Ham SW, Kim KR, Cheon HG, Lee KH, Cho H. 2-O-Carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett 2007;17:5357-5360.
129. Malamas MS, Sredy J, Moxham C, Katz A, Xu W, McDevitt R, Adebayo FO, Sawicki DR, Seestaller L, Sullivan D, Taylor JR. Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J Med Chem 2000;43:1293-1310.
130. Murthy VS, Kulkarni VM. 3D-QSAR CoMFA and CoMSIA on protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem 2002;10:2267-2282.
131. Patankar SJ, Jurs PC. Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors. J Chem Inform Comp Sci 2003;43:885-899.
132. Peterson RL, Casciotti L, Block L, Goad MEP, Tong Z, Meehan JT, Jordan RA, Vinlove MP, Markiewicz VR, Weed CA, Dorner AJ. Mechanistic toxicogenomic analysis of WAY-144112 (ertiprotafib) administration in Sprague-Dawley rats. Toxicol Appl Pharmacol 2004;196:80-94.
133. Erbe DV, Wang S, Zhang YL, Harding K, Kung L, Tam M, Stolz L, Xing Y, Furey S, Qadri A, Klaman LD, Tobin JF. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Mol Pharmacol 2005;67:69-77.
134. Shrestha S, Bhattarai BR, Cho H, Choi J-K, Cho H. PTP1B inhibitor Ertiprotafib is also a potent inhibitor of IKB kinase β (IKK-β). Bioorg Med Chem Lett 2007;17:2728-2730.
135. Brichard SM, Henquin JC. The role of vanadium in the management of diabetes. TIPS 1995;16:265-270.
136. Fantus IG, Kadota S, Deragon G, Foster B, Posner BI. Pervanadate [peroxide(s) of vanadate] mimics insulin action in rat adipocytes via activation of the insulin receptor tyrosine kinase. Biochemistry 1989;28:8864-8871.
137. Posner BI, Faure R, Burgess JW, Bevan AP, Lachance D, Zhang-Sun G, Fantus IG, Ng JB, Hall DA, Lum BS. Peroxovanadium compounds. A new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics.J Biol Chem 1994;269:4596-4604.
138. Huyer G, Liu S, Kelly J, Moffat J, Payette P, Kennedy B, Tsaprailis G, Gresser MJ, Ramachandran C. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate. J Biol Chem 1997;272:843-851.
139. Andersen HS, Iversen LF, Jeppesen CB, Branner S, Norris K, Rasmussen HB, Møller KB, Møller NPH. 2-(Oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases. J Biol Chem 2000;275:7101-7108.
140. Zhang ZY, Wang Y, Wu L, Fauman EB, Stuckey JA, Schubert HL, Saper MA, Dixon JE. The Cys(X) 5Arg catalytic motif in phosphoester hydrolysis. Biochemistry 1994;33:15266-15270.
141. Andersen HS, Olsen OH, Iversen LF, Sorensen ALP, Mortensen SB, Christensen MS, Branner S, Hansen TK, Lau JF, Jeppesen L, Moran EJ, Su J, Bakir F, Judge L, Shahbaz M, Collins T, Vo T, Newman MJ, Ripka WC, Moller NPH. Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. J Med Chem 2002;45:4443-4459.
142. Liu G, Szczepankiewicz BG, Pei Z, Janowick DA, Xin Z, Hajduk PJ, Abad-Zapatero C, Liang H, Hutchins CW, Fesik SW, Ballaron SJ, Stashko MA, Lubben T, Mika AK, Zinker BA, Trevillyan JM, Jirousek MR. Discovery and structure-activity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J Med Chem 2003;46:2093-2103.
143. Xin Z, Oost TK, Abad-Zapatero C, Hajduk PJ, Pei Z, Szczepankiewicz BG, Hutchins CW, Ballaron SJ, Stashko MA, Lubben T, Trevillyan JM, Jirousek MR, Liu G. Potent, selective inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2003;13:1887-1890.
144. Moretto AF, Kirincich SJ, Xu WX, Smith MJ, Wan ZK, Wilson DP, Follows BC, Binnun E, Joseph-McCarthy D, Foreman K, Erbe DV, Zhang YL, Tam SK, Tam SY, Lee J. Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem 2006;14:2162-2177.
145. Ahn JH, Cho SY, Ha JD, Chu SY, Jung SH, Jung YS, Baek JY, Choi IK, Shin EY, Kang SK, Kim SS, Cheon HG, Yang SD, Choi JK. Synthesis and PTP1B inhibition of 1, 2-naphthoquinone derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett 2002;12:1941-1946.
146. Cheon HG, Kim SM, Yang SD, Ha JD, Choi JK. Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: Potential development as an antihyperglycemic agent. Eur J Pharmacol 2004;485:333-339.
147. Shim YS, Kim KC, Chi DY, Lee KH, Cho H. Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett 2003;13:2561-2563.
148. Shim YS, Kim KC, Lee KA, Shrestha S, Lee KH, Kim CK, Cho H. Formylchromone derivatives as irreversible and selective inhibitors of human protein tyrosine phosphatase 1B. Kinetic and modeling studies. Bioorg Med Chem 2005;13:1325-1332.
149. Kim CK, Lee KA, Zhang H, Cho H, Lee BS. Docking Studies on formylchromone derivatives as protein tyrosine phosphatase 1B (PTP 1B) inhibitors. Bull Korean Chem Soc 2007;28:1141-1150.
150. Sachan N, Kadam SS, Kulkarni VM. Human protein tyrosine phosphatase 1B inhibitors: QSAR by genetic function approximation. J Enz Inhib Med Chem 2007;22:267-276.
151. Liljebris C, Martinsson J, Tedenborg L, Williams M, Barker E, Duffy JES, Nygren A, James S. Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B). Bioorg Med Chem 2002;10:3197-3212.
152. Tjernberg A, Hallén D, Schultz J, James S, Benkestock K, Byström S, Weigelt J. Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP 1B). Bioorg Med Chem Lett 2004;14:891-895.
153. Arabaci G, Guo XC, Beebe KD, Coggeshall KM, Pei D. α-Haloacetophenone derivatives as photoreversible covalent inhibitors of protein tyrosine phosphatases. J Am Chem Soc 1999;12:5085-5086.
154. Arabaci G, Yi T, Fu H, Porter ME, Beebe KD, Pei D. α-Bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: Structure-activity relationship. Bioorg Med Chem Lett 2002;12:3047-3050.
155. Dixit M, Tripathi BK, Srivastava AK, Goel A. Synthesis of functionalized acetophenones as protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett 2005;15:3394-3397.
156. Guertin KR, Setti L, Qi L, Dunsdon RM, Dymock BW, Jones PS, Overton H, Taylor M, Williams G, Sergi JA, Wang K, Peng Y, Renzetti M, Boyce R, Falcioni F, Garippa R, Olivier AR. Identification of a novel class of orally active pyrimido[5, 4-3][1, 2, 4]triazine-5, 7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity. Bioorg Med Chem Lett 2003;13:2895-2898.
157. Ahn JH, Cho SY, Ha JD, Kang SK, Jung SH, Kim H-M, Kim SS, Kim KR, Cheon HG, Yang S-D, Choi J-K. Protein tyrosine phosphatase 1B inhibitors: Catechols. Bull Korean Chem Soc 2003;24:1505-1508.
158. Cho SY, Baek JY, Han SS, Kang SK, Ha JD, Ahn JH, Lee JD, Kim KR, Cheon HG, Rhee SD, Yang SD, Yon GH, Pak CS, Choi JK. PTP-1B inhibitors: cyclopenta[d][1, 2]-oxazine derivatives. Bioorg Med Chem Lett 2006;16:499-502.
159. Liu G, Xin Z, Pei Z, Hajduk PJ, Abad-Zapatero C, Hutchins CW, Zhao H, Lubben TH, Ballaron SJ, Haasch DL, Kaszubska W, Rondinone CM, Trevillyan JM, Jirousek MR. Fragment screening and assembly: A highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor. J Med Chem 2003;46:4232-4235.
160. Zhao H, Liu G, Xin Z, Serby MD, Pei Z, Szczepankiewicz BG, Hajduk PJ, Abad-Zapatero C, Hutchins CW, Lubben TH, Ballaron SJ, Haasch DL, Kaszubska W, Rondinone CM, Trevillyan JM, Jirousek MR. Isoxazole carboxylic acids as protein tyrosine phosphatase 1B (PTP1B) inhibitors. Bioorg Med Chem Lett 2004;14:5543-5546.
161. Lin L, Shen Q, Chen GR, Xie J. Synthesis of triazole-linked [beta]-C-glycosyl dimers as inhibitors of PTP1B. Bioorg Med Chem 2008;16:9757-9763.
162. Saxena AK, Pandey G, Gupta S, Singh AB, Srivastava AK. Synthesis of protein tyrosine phosphatase 1B inhibitors: Model validation and docking studies. Bioorg Med Chem Lett 2009;19:2320-2323.
163. Koehn FE, Carter GT. The evolving role of natural products drug discovery. Nat Rev 2005;4:206-220.
164. Chen RM, Hu LH, An TY, Li J, Shen Q. Natural PTP1B Inhibitors from broussonetia papyrifera. Bioorg Med Chem Lett 2002;12:3387-3390.
165. Yin J, Hu R, Chen M, Tang J, Li F, Yang Y, Chen J. Effects of berberine on glucose metabolism in vitro. Metabolism 2002;51:1439-1443.
166. Ko BS, Choi SB, Park SK, Jang JS, Kim YE, Park S. Insulin sensitizing and insulinotropic action of berberine form cortidis rhizoma. Biol Pharm Bull 2005;28:1431-1437.
167. Zhou L, Yang Y, Wang X, Liu S, Shang W, Yuan G, Li F, Tang J, Chen M, Chen J. Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 2007;56:405-412.
168. Bustanji Y, Taha MO, Yousef AM, Bakri AGA. Berberine potently inhibits protein tyrosine phosphatase 1B: Investigation by docking simulation and experimental validation. J Enz Inhib Med Chem 2006;21:163-171.
169. Bustanji Y, Taha MO, Al-Masri IM, Mohammad MK. Docking simulations and in vitro assay unveil potent inhibitory action of papaverine against protein tyrosine phosphatase 1B. Biol Pharm Bull 2009;32:640-645.
170. Mitscher LA, Okwute SK, Gollapudi SR, Drake S, Avona E. Antimicrobial pterocarpans of nigerian Erythrina mildbraedii. Phytochemistry 1988;27:3449-3452.
171. Barron D, Ibrahim RK. Isoprenylated flavonoids-a survey. Phytochemistry 1996;43:921-982.
172. Na M, Hoang DM, Njamen D, Mbafor JT, Fomum ZT, Thuong PT, Ahn JS, Oh WK. Inhibitory effect of 2-arylbenzofurans from Erythrina addisoniae on protein tyrosine phosphatase-1B. Bioorg Med Chem Lett 2007;17:3868-3871.
173. Cui L, Ndinteh DT, Na M, Thuong PT, Silike-Muruumu J, Njamen D, Mbafor JT, Fomum ZT, Ahn JS, Oh WK. Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod 2007;70:1039-1042.
174. Cui L, Thuong PT, Lee HS, Ndinteh DT, Mbafor JT, Fomum ZT, Oh WK. Flavanones from the stem bark of Erythrina abyssinica. Bioorg Med Chem 2008;16:10356-10362.
175. Lakshmi BS, Sujatha S, Anand S, Sangeetha KN, Narayanan RB, Katiyar C, Kanaujia A, Duggar R, Singh Y, Srinivas K, Bansal V, Sarin S, Tandon R, Sharma S, Singh S. Cinnamic acid, from the bark of Cinnamomum cassia, regulates glucose transport via activation of GLUT4 on L6 myotubes in a phosphatidylinositol 3-kinase-independent manner. J Diabetes 2009;1:99-106.
176. Moran EJ, Sarshr S, Cargill JF, Shahbaz MM, Lio A, Mjalli AMM, Armstrong RW. Radio frequency tag encoded combinatorial library method for the discovery of tripeptide-substituted cinnamic acid inhibitors of the protein tyrosine phosphatase PTP1B. J Am Chem Soc 1995;117:10787-10788.
177. Fu H, Park J, Pei D. Peptidyl aldehydes as reversible covalent inhibitors of protein tyrosine phosphatases. Biochemistry 2002;41:10700-10709.
178. Cui L, Na M, Oh H, Bae EY, Jeong DG, Ryu SE, Kim S, Kim Y, Oh WK, Ahn JS. Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett 2006;16:1426-1429.
179. Kim S, Na M, Oh H, Jang J, Sohn CB, Kim BY, Oh WK, Ahn JS. PTP1B inhibitory activity of kaurane diterpenes isolated from Siegesbeckia glabrescens. J Enz Inhib Med Chem 2006;21:379-383.
180. Na M, Oh WK, Kim YH, Cai XF, Kim S, Kim BY, Ahn JS. Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum. Bioorg Med Chem Lett 2006;16:3061-3064.
181. Na M, Cui L, Min BS, Bae K, Yoo JK, Kim BY, Oh WK, Ahn JS. Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett 2006;16:3273-3276.
182. An TY, Hu LH, Chen RM, Chen ZL, LI J, Shen Q. Anti-diabetes Agents-I: Tetralone derivative from Juglans regia. Chinese Chem Lett 2003;14:489-490.
183. Li S, An TY, Li J, Shen Q, Lou FC, Hu LH. PTP1B inhibitors from Saussrurea lappa. J Asian Nat Prod Res 2006;8:281-286.
184. Li YF, Hu LH, Lou FC, Li J, Shen Q. PTP1B inhibitors from Ardisia japonica. J Asian Nat Prod Res 2005;7:13-18.
185. Oh WK, Lee CH, Lee MS, Bae EY, Sohn CB, Oh H, Kim BY, Ahn JS. Antidiabetic effects of extracts from Psidium guajava. J Ethnopharmacol 2005;96:411-415.
186. Imoto M, Kakeya H, Sawa T, Chigusa H, Hamada M, Takeuchi T, Umezawa K. Dephostatin, a novel proteintyrosine phosphatase inhibitor produced by Streptomyces. J Antibiot (Tokyo). 1993;45:1342-1346.
187. Umezawa K, Kawakami M, Watanabe T. Molecular design and biological activities of protein tyrosine phosphatase inhibitors. Pharmacol Ther 2003;99:15-24.
188. Sun T, Wang Q, Yu Z, Zhang Y, Guo Y, Chen K, Shen X, Jiang H. Hyrtiosal, a PTP1B inhibitor from the marine sponge Hyrtios erectus, shows extensive cellular effects on PI3K/AKT activation, glucose transport, and TGFβ/Smad2 signaling. Chem Bio Chem 2007;8:187-193.